FEMY
What one share of Femasys holds
Surgical and Medical Instruments and Apparatus
We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets.
Femasys’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.77 |
|---|---|
| Profit | −$3.96 |
| Capex (buildings and equipment) | $0.14 |
| Free cash flow | −$6.08 |
| Cash and investments | $0.48 |
| Debt | $1.05 |
| Book value | $1.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $21.63 | −$144.08 | $0.17 | −$102.96 | — | −$1,043 |
| 2021 | $3.52 | −$22.46 | $0.91 | −$24.55 | — | $44.62 |
| 2022 | $2.04 | −$19.29 | $0.69 | −$18.86 | — | $25.68 |
| 2023 | $1.39 | −$18.52 | $0.19 | −$14.85 | — | $16.95 |
| 2024 | $1.46 | −$16.90 | $0.68 | −$18.15 | — | $1.97 |
| 2025 | $1.16 | −$9.42 | $0.27 | −$9.72 | — | $1.97 |